Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 9/20 | 0.45 |
| ▸ | HTR2A | P28223 | 8/20 | 0.45 |
| ▸ | HTR2B | P41595 | 4/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.35 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.35 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24163285 | 0.85 | HTR2C (0.50) | HTR2CHTR2AHTR2BKDM4ECYP3A4 | |
| SCHEMBL26065401 | 0.73 | KCNA3 (0.39) | KDM4EALDH1A1MAPTCYP3A4MEN1 | |
| SCHEMBL8354843 | 0.73 | HTR2A (0.47) | HTR2CHTR2AHTR2BKDM4EALDH1A1 | |
| SCHEMBL11334545 | 0.72 | HTR2A (0.46) | HTR2CHTR2AHTR2BKDM4EALDH1A1 | |
| SCHEMBL28387488 | 0.69 | NCEH1 (0.60) | MAPTMEN1KMT2A | |
| SCHEMBL27051615 | 0.69 | HTR2A (0.43) | HTR2CHTR2AHTR2BKDM4EALDH1A1 | |
| SCHEMBL8670242 | 0.68 | CYP1A1 (0.40) | HTR2CHTR2AHTR2BALDH1A1MEN1 | |
| SCHEMBL6637551 | 0.68 | HTR2A (0.43) | HTR2CHTR2AHTR2BKDM4EALDH1A1 | |
| SCHEMBL8564056 | 0.68 | CA1 (0.48) | HTR2CHTR2AKDM4EALDH1A1MAPT | |
| SCHEMBL29761716 | 0.67 | CYP2A6 (0.55) | HTR2CHTR2AHTR2BKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230265045-A1 | PHENALKYLAMINES AND METHODS OF TREATING MOOD DISORDERS | GILGAMESH PHARMACEUTICALS, INC. (US) | 2023-08-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230265045-A1 | PHENALKYLAMINES AND METHODS OF TREATING MOOD DISORDERS | PNMT, HTR2C, HTR2A | HTR2C 2/4885HTR2A 3/4885HTR2B 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.